All Wales Management of Refugees at risk of Drug-Resistant Tuberculosis





STEP 1 INFORMATION

Risk of drug-resistant TB

contact of drug-resistant

Assessment

Known household

History of prison

• HIV+, IVDU or Hep C+

• Failure to complete

previous TB treatment

DID YOU KNOW?

Ukraine has one of the highest rates of Multi Drug-Resistant Tuberculosis in the world.

Current version: 1.0

The humanitarian crisis in Ukraine has prompted the arrival of refugees into the UK, resulting in an impending public health situation.

Find out more from the TB clinical lead 🔪 for Wales



Asylum seekers and refugees are at high-risk of reactivation of Tuberculosis. Early screening, particularly to detect active TB, is vital to exclude ongoing transmission and ensure treatment success.

Assessment and management should be delivered by designated TB teams within each health board.

STEP 1: ASSESSMENT

Symptom checklist

- ☑ Cough
- Weight loss

History checklist

- ☑ Past history of TB (especially recent treatment) interruption due to conflict)?
- ☑ BCG vaccination status?
- ☑ Risk of drug-resistant TB? (1)
- ✓ Nutritional status?
- ✓ Immunosuppression?

STEP 2: INVESTIGATE (all patients)

Age <11years, if asymptomatic

IGRA blood test (or TST if <2 years)

and other bloods (BBV , LFT, FBC, Vit D)

and Chest x-ray if IGRA or TST positive

Age ≥11 years, or <11 years with symptoms

Bloods (IGRA, BBV , LFT, FBC, Vit D)

and Chest x-ray

STEP 2 INFORMATION INVESTIGATE

BBV Test

 HIV test HCV antibody

• Hep B sAg

STEP 3: MANAGE

IGRA or TST (-ve) and Normal CXR and asymptomatic

INFORM AND ADVISE DISCHARGE

IGRA or TST (+ve) and Normal CXR and asymptomatic

CONSIDER LATENT TB

Review of LTBI cases

IGRA or TST (+ve) and Normal CXR and symptomatic

CONSIDER NON-PULMONARY ACTIVE TB

Urgent clinical review by TB service and further investigations (samples for TB culture)

Abnormal CXR with/without symptoms

INVESTIGATE FOR ACTIVE TB

Send 2x Sputa for TB smear, PCR (using code UKR2022) and culture to determine sensitivity to Rifampicin

1 LATENT TB INFECTION

STEP 3 INFORMATION

Inform and advise patient

Collect sputum if productive

MANAGE

Clinical review at 3-6 months with chest x-ray

Consider LTBI treatment, noting risk of drug

resistance

1 TB IN CHILDREN

Make every effort to get a microbiological specimen in children

Babies need to be seen by a specialist as a matter of urgency

Please discuss any patients <16yrs who are being investigated for Active TB with paediatric ID in UHW, or the tertiary ID services in Alder Hey (in BCUHB)

Find out more about TB in children here



Determine drug sensitivity

RIFAMPICIN SENSITIVE

Start standard WHO Quadruple therapy

Wait for full sensitivities

Admit to local hospital as appropriate

Discuss in MDT if concerns

RIFAMPICIN RESISTANT

Assume MDR/XDR-TB

Refer to hospital with negative pressure rooms

Inform Public Health

Follow WHO Guidelines

 BBV: Blood borne virus screen
CXR: Chest x-ray ID: Infectious diseases

IGRA: Intraferon Gamma Release Assay LTBI: Latent TB infection MDR: Multi-drug resistant

TST: Tuberculin Skin Test

XDR: Extensively-drug resistant